A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase–primase inhibitors in their mode of interaction with the antiviral target

Objectives To investigate the mechanism of action of the helicase–primase inhibitors (HPIs) BAY 57-1293 and BILS 22 BS by selection and characterization of drug-resistant herpes simplex virus (HSV)-1 mutants. Methods HSV-1 mutants were selected using BAY 57-1293 in Vero cells. Resistance mutations i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of antimicrobial chemotherapy 2008-05, Vol.61 (5), p.1044-1047
Hauptverfasser:	Biswas, Subhajit, Kleymann, Gerald, Swift, Mihaiela, Tiley, Laurence S., Lyall, Jonathan, Aguirre-Hernández, Jesús, Field, Hugh J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral Agents - pharmacology BAY 57-1293 BILS 22 BS Biological and medical sciences Chemotherapy DNA Helicases - antagonists & inhibitors DNA Helicases - genetics DNA Primase - antagonists & inhibitors DNA Primase - genetics Dose-Response Relationship, Drug Drug resistance Drug Resistance, Viral - genetics herpes simplex virus Herpes simplex virus 1 Herpes viruses Herpesvirus 1, Human - drug effects Herpesvirus 1, Human - enzymology Herpesvirus 1, Human - genetics Inhibitor drugs Medical sciences Mutation Pharmacology. Drug treatments Pyridines - pharmacology Thiazoles - pharmacology Viral Proteins - antagonists & inhibitors Viral Proteins - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!